Cited by 277Liver Disease and TransplantationLiver physiology and pathologyLiver Disease Diagnosis and Treatment

The DOI matches its Crossref record; 189 of the 194 references it cites were found in a registry or an index.

Angiogenesis in chronic liver disease and its complications: Angiogenesis in CLD

Open access

Coulon, Stephanie, Heindryckx, Femke, Geerts, Anja, Van Steenkiste, Christophe, Colle, Isabelle, Van Vlierberghe, Hans·2011·Liver International

DOI 10.1111/j.1478-3231.2010.02369.x

Open this paper in CoChat — free account Open PDF

Abstract

Nowadays, liver cancer, cirrhosis and other liver-related diseases are the fifth most common cause of mortality in the UK. Furthermore, chronic liver diseases (CLDs) are one of the major causes of death, which are still increasing year-on-year. Therefore, knowledge about the pathophysiology of CLDs and its complications is of uttermost importance. The goal of this review is to clarify the role of angiogenesis in the disease progression of various liver diseases. Looking closer at the pathophysiology of portal hypertension (PH), fibrosis, cirrhosis, non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), we find that angiogenesis is a recurring factor in the disease progression. In PH, several factors involved in its pathogenesis, such as hypoxia, oxidative stress, inflammation and shear stress are potential mediators for the angiogenic response. The progression from fibrosis to cirrhosis, the end-point of CLDs, is distinguished by a prolonged inflammatory and fibrogenic process that leads to an abnormal angioarchitecture distinctive for cirrhosis. In several stages of NASH, a link might be made between the disease progression and hepatic microvasculature changes. HCC is one of the most vascular solid tumours in which angiogenesis plays an important role in its development, progression and metastasis. The close relationship between the progression of CLDs and angiogenesis emphasises the need for anti-angiogenic therapy as a tool for blocking or slowing down the disease progression. The fact that angiogenesis plays a pivotal role in CLDs gives rise to new opportunities for treating CLDs and its complications.

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2010.02369.x

Cites

189 of 189 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,379
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
Söker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Pàez‐Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,373
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,956
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz‐Muñoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,739
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., Mol, M. D., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,708
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D. P., Wilhelm, S. M., Lynch, M. J., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,539
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins
Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J. M., Taipale, J., Petrova, T. V., Jeltsch, M., Jackson, D. G., Talikka, M., Rauvala, H., et al. (2003) · Nature Immunology · doi:10.1038/ni1013 · Cited by 1,441
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,437
Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice
Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M. A., Fukumura, D., Jain, R. K., & Alitalo, K. K. (1997) · Science · doi:10.1126/science.276.5317.1423 · Cited by 1,279
Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor
Appelhoff, R. J., Tian, Y.-M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., & Gleadle, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406026200 · Cited by 1,108
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,011
Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
Mazzone, M., Dettori, D., de Oliveira, R. L., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P. J., de Almodóvar, C. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 828
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 788
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
Autiero, M., Waltenberger, J. L., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Krøll, J., Plaisance, S., Mol, M. D., Bono, F., et al. (2003) · Nature Medicine · doi:10.1038/nm884 · Cited by 775
Hypoxia and cancer
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S. N., Alsinet, C., Tovar, V., Roayaie, S., Mínguez, B., Solé, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 734
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720
The codependence of angiogenesis and chronic inflammation
Jackson, J. R., Seed, M. P., Kircher, C. H., Willoughby, D. A., & Winkler, J. D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194526 · Cited by 692
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
Dawson, D. W., Pearce, S. F. A., Zhong, R., Silverstein, R. L., Frazier, W. A., & Bouck, N. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.707 · Cited by 676
A novel endothelial-specific membrane protein is a marker of cell-cell contacts.
Lampugnani, M. G., Resnati, M., Raiteri, M., Pigott, R., Pisacane, A., Houen, G., Ruco, L., & Dejana, E. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.118.6.1511 · Cited by 632
Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins
Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D., Hynes, R. O., & Hodivala‐Dilke, K. (2002) · Nature Medicine · doi:10.1038/nm0102-27 · Cited by 627
Endostatin Induces Endothelial Cell Apoptosis
Dhanabal, M., Ramchandran, R., Waterman, M. J. F., Lu, H. A. J., Knebelmann, B., Segal, M. S., & Sukhatme, V. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11721 · Cited by 582
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561
Role of MAP kinase in tumor progression and invasion
Reddy, K. B., Nabha, S. M., & Atanaskova, N. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023781114568 · Cited by 512
Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications
Friedman, S. L. (2004) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0055 · Cited by 508
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Siegel, A. B., Cohen, E. I., Ocean, A. J., Lehrer, D., Goldenberg, A. S., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A. D., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 505
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 479
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J. P., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T. R., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 465
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 398
Signal transduction by β-catenin
Gumbiner, B. M. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80104-9 · Cited by 394
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K. E., Sheehan, S., Hale, K., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Biological consequences of tumor hypoxia
ckel, M. H., & Vaupel, P. W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90211-8 · Cited by 384
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G. H., & Torbenson, M. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0941 · Cited by 382
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 368
Mice Lacking the Vascular Endothelial Growth Factor-B Gene ( Vegfb ) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia
Bellomo, D., Headrick, J. P., Silins, G. U., Paterson, C. A., Thomas, P. S., Gartside, M. G., Mould, A. W., Cahill, M. M., Tonks, I. D., Grimmond, S. M., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.2.e29 · Cited by 351
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells†
Aleffi, S., Petrai, I., Bertolani, C., Parola, M., Colombatto, S., Novo, E., Vizzutti, F., Anania, F. A., Milani, S., Rombouts, K., et al. (2005) · Hepatology · doi:10.1002/hep.20965 · Cited by 350
Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
Claesson, L., Welsh, M., Ito, N., Anand‐Apte, B., Söker, S., Zetter, B. R., O’Reilly, M. S., & Folkman, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5579 · Cited by 350
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis†
Schiffer, E. R. C., Housset, C., Cacheux, W., Wendum, D., Desbois‐Mouthon, C., Rey, C., Clergue, F., Poupon, R. Y., Barbu, V. D., & Rosmorduc, O. (2005) · Hepatology · doi:10.1002/hep.20538 · Cited by 338
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A. O., Glover, K. Y., Davila, M. L., & Abbruzzese, J. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3301 · Cited by 334
Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
Bellentani, S., & Marino, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31820-4 · Cited by 322
Pathophysiology of nonalcoholic steatohepatitis.
McCullough, A. J. (2006) · PubMed · doi:10.1097/01.mcg.0000168645.86658.22 · Cited by 319
Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins
Kevil, C. G., Payne, D. K., Mire, E., & Alexander, J. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.15099 · Cited by 318
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION
Bosch, J., Pizcueta, P. M., Feu, F., Fernández, M., & García‐Pagán, J. C. (1992) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00175-8 · Cited by 314
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Wu, Y., Yanase, K., Namisaki, T., Yamazaki, M., et al. (2003) · Gut · doi:10.1136/gut.52.9.1347 · Cited by 307
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K. Y., Wang, X., Morris, J. S., Brown, T. D., Rashid, A., Dancey, J. E., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 305
Integrins and Angiogenesis
Stupack, D. G., & Cheresh, D. A. (2004) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)64009-9 · Cited by 303
Pathophysiology of Nonalcoholic Steatohepatitis
Başaranoğlu, M. (2009) · Cited by 293
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Faivre, S. J., Raymond, É., Boucher, É., Douillard, J.-Y., Lim, H. Y., Kim, J. S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S. E., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70171-8 · Cited by 290
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M. S., Lenz, H., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284
Identification of a new fibroblast growth factor receptor, FGFR5.
Sleeman, M. A., Fraser, J. W., McDonald, M., Yuan, S.-N., White, D., Grandison, P., Kumble, K. D., Watson, J. D., & Murison, J. (2001) · Gene · doi:10.1016/s0378-1119(01)00518-2 · Cited by 284
Platelet-Derived Growth Factor is Angiogenic In Vivo
Risau, W., Drexler, H. C. A., Mironov, V., Smits, A., Siegbahn, A., Funa, K., & Heldin, C. (1992) · Growth Factors · doi:10.3109/08977199209046408 · Cited by 283
PDGF and Vessel Maturation
Hellberg, C. B., Östman, A., & Heldin, C. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_7 · Cited by 272
Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis
Cusi, K. J. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.009 · Cited by 270
Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats
Tugues, S., Fernández‐Varo, G., Muñoz, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W., & Morales‐Ruiz, M. (2007) · Hepatology · doi:10.1002/hep.21921 · Cited by 263
Increased Expression of Vascular Endothelial Growth Factor and Angiogenesis in the Early Stage of Multistep Hepatocarcinogenesis
Park, Y. N., Kim, Y., Yang, K. M., & Park, C. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-1061-ieoveg · Cited by 261
Pathophysiology of Nonalcoholic Steatohepatitis
Watanabe, S. (2017) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.63.230 · Cited by 257
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
de Veire, S. V., Stalmans, I., Heindryckx, F., Oura, H., Tijeras‐Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 255
Self-citation
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Zhu, A. X., Stuart, K. E., Blaszkowsky, L. S., Muzikansky, A., Reitberg, D. P., Clark, J. W., Enzinger, P. C., Bhargava, P., Meyerhardt, J. A., Horgan, K. E., et al. (2007) · Cancer · doi:10.1002/cncr.22829 · Cited by 248
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes
Safadi, R., Ohta, M., Alvarez, C. E., Fiel, M. I., Bansal, M., Mehal, W. Z., & Friedman, S. L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.062 · Cited by 239
Pathogenesis of nonalcoholic steatohepatitis
Liu, W., Baker, R. D., Bhatia, T., Zhu, L., & Baker, S. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2161-x · Cited by 233
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Newell, P., Toffanin, S., Villanueva, A., Chiang, D. Y., Mínguez, B., Cabellos, L., Savić, R., Hoshida, Y., Lim, K. H., Melgar‐Lesmes, P., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.028 · Cited by 227
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Huynh, H. T., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A. Y. F., Chow, P. K. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 225
Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells
Novo, E., Cannito, S., Zamara, E., di Bonzo, L. V., Caligiuri, A., Cravanzola, C., Compagnone, A., Colombatto, S., Marra, F., Pinzani, M., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060887 · Cited by 222
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
Fernández, M., Mejías, M., Angermayr, B., García‐Pagán, J. C., Rodés, J., & Bosch, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.022 · Cited by 217
Normal Development, Wound Healing, and Adenovirus Susceptibility in β5-Deficient Mice
Huang, X., Griffiths, M., Wu, J., Farese, R. V., & Sheppard, D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.755-759.2000 · Cited by 215
Chemokines in liver inflammation and fibrosis
Marra, F. (2002) · Frontiers in bioscience · doi:10.2741/a887 · Cited by 214
Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice
McCuskey, R. S., Ito, Y., Robertson, G. R., McCuskey, M. K., Perry, M. A., & Farrell, G. C. (2004) · Hepatology · doi:10.1002/hep.20302 · Cited by 212
Molecular Cloning, Expression, and Characterization of Angiopoietin-related Protein
Kim, I., Moon, S.-O., Koh, K. N., Kim, H., Uhm, C.-S., Kwak, H. J., Kim, N.-G., & Koh, G. Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26523 · Cited by 212
Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery
Chao, Y., Li, C., Chau, G., Chen, C., King, K., Lui, W., Yen, S., Chang, F., Chan, W., & Lee, S. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.10.002 · Cited by 209
Integrins and angiogenesis: A sticky business
Serini, G., Valdembri, D., & Bussolino, F. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.020 · Cited by 207
Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse Embryos
Haiko, P., Mäkinen, T., Keskitalo, S., Taipale, J., Karkkainen, M. J., Baldwin, M. E., Stacker, S. A., Achen, M. G., & Alitalo, K. K. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02214-07 · Cited by 199
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H. N., Cancilla, B., Chu, F., Hitchcock‐Bryan, S., Sherman, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 199
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC)
Louafi, S., Boige, V., Ducreux, M. P., Bonyhay, L., Mansourbakht, T., de Baère, T., Asnacios, A., Hannoun, L., Poynard, T., & Taı̈eb, J. (2007) · Cancer · doi:10.1002/cncr.22532 · Cited by 196
Pathogenesis of Non-alcoholic Steatohepatitis: Human Data
Edmison, J. M., & McCullough, A. J. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.011 · Cited by 195
Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1)
Greenaway, J. B., Lawler, J., Moorehead, R. A., BORNSTEIN, P. K., LaMarre, J., & Petrik, J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20904 · Cited by 187
Angiogenesis and inflammation face off
Imhof, B. A., & Aurrand‐Lions, M. (2006) · Nature Medicine · doi:10.1038/nm0206-171 · Cited by 181
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats
Fernández, M., Mejías, M., García‐Pras, E., Méndez, R., García‐Pagán, J. C., & Bosch, J. (2007) · Hepatology · doi:10.1002/hep.21785 · Cited by 181
Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells
Ankoma‐Sey, V., Wang, Y., & Dai, Z. (2000) · Hepatology · doi:10.1002/hep.510310122 · Cited by 179
VE-Cadherin-Mediated Cell-Cell Interaction Suppresses Sprouting via Signaling to MLC2 Phosphorylation
Abraham, S., Yeo, M., Montero‐Balaguer, M., Paterson, H., Dejana, E., Marshall, C. J., & Mavria, G. (2009) · Current Biology · doi:10.1016/j.cub.2009.02.057 · Cited by 163
Microvessel Density, Vascular Endothelial Growth Factor and Its Receptors Flt-1 and Flk-1/KDR in Hepatocellular Carcinoma
Ng, I. O., Poon, R. T. P., Lee, J. M. F., Fan, S. T., NG, M. M., & Tso, W. K. (2001) · American Journal of Clinical Pathology · doi:10.1309/fxnl-qtn1-94fh-ab3a · Cited by 162
Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells.
Sachinidis, A., Locher, R., Vetter, W., Tatje, D., & Hoppe, J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86937-x · Cited by 154
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial
Rimassa, L., & Santoro, A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.41 · Cited by 153
Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis.
Marx, M., Perlmutter, R. A., & Madri, J. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116936 · Cited by 152
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Huynh, H. T., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150
Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival
Huang, G. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i11.1705 · Cited by 149
Leptin‐mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats†
Kitade, M., Yoshiji, H., Kojima, H., Ikenaka, Y., Noguchi, R., Kaji, K., Yoshii, J., Yanase, K., Namisaki, T., Asada, K., et al. (2006) · Hepatology · doi:10.1002/hep.21338 · Cited by 147
ET-1 induced alterations of hepatic microcirculation: sinusoidal and extrasinusoidal sites of action
Bauer, M. W., Zhang, J. X., Bauer, I., & Clemens, M. G. (1994) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1994.267.1.g143 · Cited by 140
Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen‐induced and collagen‐induced models of arthritis
Mould, A. W., Tonks, I. D., Cahill, M. M., Pettit, A. R., Thomas, R., Hayward, N. K., & Kay, G. F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11232 · Cited by 138
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
Rizell, M., Andersson, M., Cahlin, C., Hafström, L., Olausson, M., & Lindnér, P. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0733-3 · Cited by 134
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
Hsu, C., Yang, T.-S., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L.-T., Chen, P.-J., Lin, Z.-Z., Chao, T.-Y., & Cheng, A.-L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605580 · Cited by 132
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
Huynh, H. T., Ngo, V. C., Koong, H. N., Poon, D. Y. H., Choo, S. P., Thng, C. H., Chow, P. K. H., Ong, H. S., Chung, A. Y. F., & Soo, K. C. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00692.x · Cited by 130
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin‐2 and hypoxia‐induced factor‐1a
Wada, H., Nagano, H., Yamamoto, H., Yang, Y., Kondo, M., Ota, H., Nakamura, M., Yoshioka, S., Kato, H., Damdinsuren, B., et al. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01243.x · Cited by 130
Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
Yao, D., Wu, X., Zhu, Y. M., Shi, G.-S., Dong, Z., Yao, D.-B., Wu, W., Qiu, L., & Meng, X. (2005) · PubMed · Cited by 128
Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro
Bootle-Wilbraham, C. A., Tazzyman, S. J., Thompson, W. D., Stirk, C. M., & Lewis, C. E. (2001) · Angiogenesis · doi:10.1023/a:1016076121918 · Cited by 126
Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver
Zhang, J. X., Bauer, M. W., & Clemens, M. G. (1995) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1995.269.2.g269 · Cited by 123
High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies
Poon, R. T. P., Lau, C. P.-Y., Pang, R. W. C., Ng, K. K., Yuen, J. H. F., & Fan, S. T. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9366-z · Cited by 117
Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism.
Camussi, G., Montrucchio, G. G., Lupia, E., Martino, A. D., Perona, L., Arese, M., Vercellone, A., Toniolo, A., & Bussolino, F. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6492 · Cited by 107
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Patyna, S. J., Laird, A., Mendel, D. B., O’Farrell, A.-M., Liang, C., Guan, H., Vojkovský, T., Vasile, S., Wang, X., Chen, J. W., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0333 · Cited by 105
The biology of vascular endothelial growth factor-B (VEGF-B)
Nash, A. D., Baca, M., Wright, C. E., & Scotney, P. D. (2005) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.02.007 · Cited by 103
Fat distribution and storage: how much, where, and how?
Weiss, R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0125 · Cited by 102
Prognostic Factors and Recurrence of Small Hepatocellular Carcinoma after Hepatic Resection or Microwave Ablation: A Retrospective Study
Wang, Z., Liang, P., Dong, B., Yu, X., & Yu, D. J. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0310-0 · Cited by 100
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
Huynh, H. T., Ngo, V. C., Koong, H. N., Poon, D. Y. H., Choo, S. P., Toh, H. C., Thng, C. H., Chow, P. K. H., Ong, H. S., Chung, A. Y. F., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.008 · Cited by 100
Multidrug resistance gene (MDR‐1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection
Kato, A., Miyazaki, M., Ambiru, S., Yoshitomi, H., Ito, H., Nakagawa, K., Shimizu, H., Yokosuka, O., & Nakajima, N. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1129 · Cited by 97
Pathophysiology of portal hypertension.
Cichoz-Lach, H., Celiński, K., Słomka, M., & Kasztelan‐Szczerbińska, B. (2008) · PubMed · Cited by 97
Phosphatidylinositol 3′-Kinase-independent p70 S6 Kinase Activation by Fibroblast Growth Factor Receptor-1 Is Important for Proliferation but Not Differentiation of Endothelial Cells
Kanda, S., Hodgkin, M. N., Woodfield, R. J., Wakelam, M. J. O., Thomas, G., & Claesson, L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23347 · Cited by 93
Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
Koeberle, D., Montemurro, M., Samaras, P., Majno, P. E., Simcock, M., Limacher, A., Lerch, S., Kovács, K. J., Inauen, R. I., Hess, V., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0316 · Cited by 92
The management of alcoholic liver disease
Stewart, S. F., & Day, C. P. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00427-0 · Cited by 90
Angiostatin Diminishes Activation of the Mitogen-Activated Protein Kinases ERK-1 and ERK-2 in Human Dermal Microvascular Endothelial Cells
Redlitz, A., Daum, G., & Sage, E. H. (1999) · Journal of Vascular Research · doi:10.1159/000025623 · Cited by 88
Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma
Hsu, C., Chen, C., Chen, L., Wu, C., Yang, P., Lai, M., Lee, P., & Cheng, A. (2003) · Oncology · doi:10.1159/000074477 · Cited by 87
Fibroblast growth factors as angiogenesis factors: New insights into their mechanism of action
Klein, S. S., Roghani, M., & Rifkin, D. B. (1997) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-9006-9_7 · Cited by 87
The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line
Huang, M. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00280-8 · Cited by 84
VEGF‐A, VEGF‐D and VEGF‐DΔNΔC induced intimal hyperplasia in carotid arteries
Bhardwaj, S., Roy, H., Heikura, T., & Ylä‐Herttuala, S. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01555.x · Cited by 79
mTOR inhibitors for hepatocellular cancer: a forward-moving target
Treiber, G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.2.247 · Cited by 76
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus
Zhou, J., Tang, Z., Fan, J., Wu, Z.-Q., Li, X., Liu, Y., Liu, F., Sun, H., & Ye, S. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050009 · Cited by 74
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
Finn, R. S., Bentley, G. V., Britten, C. D., Amado, R. G., & Busuttil, R. W. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01762.x · Cited by 73
The Potential of Angiogenesis Soluble Markers in Chronic Hepatitis C *
Salcedo-Mora, X., Medina, J., Sanz-Cameno, P., Garcı́a-Buey, L., Martín‐Vílchez, S., Borque, M. J., López‐Cabrera, M., & Moreno‐Otero, R. (2005) · Hepatology · doi:10.1002/hep.20828 · Cited by 73
Inhibition of Hepatic Stellate Cell Proliferation and Activation by the Semisynthetic Analogue of Fumagillin Tnp–470 in Rats
Wang, Y. Q., Ikeda, K., Ikebe, T., Hirakawa, K., Sowa, M., Nakatani, K., Kawada, N., & Kaneda, K. (2000) · Hepatology · doi:10.1053/jhep.2000.18658 · Cited by 73
Role of Kupffer cells in gut ischemia/reperfusion-induced hepatic microvascular dysfunction in mice
Horie, Y., Wolf, R., Russell, J., Shanley, T. P., & Granger, D. N. (1997) · Hepatology · doi:10.1002/hep.510260617 · Cited by 72
Rat liver endothelial cells isolated by anti-CD31 immunomagnetic separation lack fenestrae and sieve plates
DeLeve, L. D., Wang, X., McCuskey, M. K., & McCuskey, R. S. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00229.2006 · Cited by 71
Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study
Geerts, A. M., Vriese, A. S. D., Vanheule, E., Vlierberghe, H. V., Mortier, S., Cheung, K., Demetter, P., Lameire, N. H., Vos, M. D., & Colle, I. O. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01308.x · Cited by 71
Self-citation
III. Leukocyte adhesion and transmigration in the liver vasculature*
Jaeschke, H., & Smith, C. W. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.6.g1169 · Cited by 71
Expression of the platelet‐derived growth factor β receptor during organogenesis and tissue differentiation in the mouse embryo
Shinbrot, E., Peters, K. G., & Williams, L. T. (1994) · Developmental Dynamics · doi:10.1002/aja.1001990302 · Cited by 70
Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma
Ho, M., Chen, C., Lee, H., Hsieh, F., Shun, C., Chang, C., Lai, Y.-T., & Lee, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.005 · Cited by 69
Modulation of Angiogenesis in Vitro by Laminin-Entactin Complex
Nicosia, R. F., Bonanno, E., Smith, M., & Yurchenco, P. D. (1994) · Developmental Biology · doi:10.1006/dbio.1994.1191 · Cited by 68
Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico‐pathological parameters
Kanda, M., Nomoto, S., Nishikawa, Y., Sugimoto, H., Kanazumi, N., Takeda, S., & Nakao, A. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21095 · Cited by 68
Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles
Simpson, K. J., Henderson, N. C., Bone‐Larson, C. L., Lukacs, N. W., Hogaboam, C. M., & Kunkel, S. L. (2003) · Clinical Science · doi:10.1042/cs20020137 · Cited by 68
Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1α inhibition
Du, G., Han, G., Zhang, S., Lin, H., Wu, X., Wang, M., Ji, L., Lu, L., Yu, L., & Liang, W. P. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.014 · Cited by 67
Hepatocellular Carcinoma
Maïo, M. D., Maio, E. D., Perrone, F., Pignata, S., & Daniele, B. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200211002-00007 · Cited by 65
Detection of characteristic sub pathway network for angiogenesis based on the comprehensive pathway network
Huang, Y., & Li, S. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s1-s32 · Cited by 64
Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study
Jeng, K. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i5.643 · Cited by 64
Inflammation: a way to understanding the evolution of portal hypertension
Aller, M., Arias, J.-L., Cruz, A., & Árias, J. (2007) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-4-44 · Cited by 63
Mast cells and angiogenesis
Levi‐Schaffer, F., & Pe'er, J. (2001) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2001.01041.x · Cited by 62
Role of Placental Growth Factor in Mesenteric Neoangiogenesis in a Mouse Model of Portal Hypertension
Steenkiste, C. V., Geerts, A. M., Vanheule, E., Vlierberghe, H. V., Vos, F. D., Olievier, K., Casteleyn, C. R., Laukens, D., Vos, M. D., Stassen, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.068 · Cited by 61
Self-citation
Blockade of renin–angiotensin system in antifibrotic therapy
Yoshiji, H., Kuriyama, S., & Fukui, H. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04663.x · Cited by 60
NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats
Angermayr, B., Fernández, M., Mejías, M., Gracia‐Sancho, J., García‐Pagán, J. C., & Bosch, J. (2006) · Gut · doi:10.1136/gut.2005.088013 · Cited by 60
Hepatocyte growth factor, vascular endothelial growth factor, glial cell-derived neurotrophic factor and nerve growth factor are differentially affected by early chronic ethanol or red wine intake
Fiore, M., Mancinelli, R., Aloe, L., Giovanni Laviola, A., Sornelli, F., Vitali, M., & Ceccanti, M. (2009) · Toxicology Letters · doi:10.1016/j.toxlet.2009.04.013 · Cited by 54
Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection
Cui, J. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i10.1533 · Cited by 53
Platelet-derived growth factor receptors on macrovascular endothelial cells mediate relaxation via nitric oxide in rat aorta.
Cunningham, L., Brecher, P. I., & Cohen, R. A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115667 · Cited by 51
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma
Iavarone, M. A., Lampertico, P., Iannuzzi, F., Manenti, E., Donato, M. F., Arosio, E., Bertolini, F., Primignani, M., Sangiovanni, A., & Colombo, M. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00782.x · Cited by 50
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines
Morelli, M. P., Brown, A. M., Pitts, T. M., Tentler, J. J., Ciardiello, F., Ryan, A. J., Jürgensmeier, J. M., & Eckhardt, S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0380 · Cited by 50
Transcriptional regulation of stellate cell activation
Friedman, S. L. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04585.x · Cited by 47
Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status
Wang‐Rodriguez, J., Urquidi, V., Rivard, A. L., & Steve Goodison, B. (2003) · Breast Cancer Research · doi:10.1186/bcr620 · Cited by 47
Correlation of VEGF production with IL1α and IL6 secretion by human pituitary adenoma cells
Borg, S. A., Kerry, K., Royds, J. A., Battersby, R. D. E., & Jones, T. H. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01843 · Cited by 45
Transcriptional Regulation in Hepatic Stellate Cells
Eng, F. J., & Friedman, S. L. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17553 · Cited by 44
The Complex Functions of Mast Cells in Chronic Human Liver Diseases
Franceschini, B., Ceva‐Grimaldi, G., Russo, C., Dioguardi, N., & Grizzi, F. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9082-8 · Cited by 44
Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181af5e35 · Cited by 43
Crosstalk between angiogenesis, cytokeratin-18, and insulinresistance in the progression of non-alcoholic steatohepatitis
Kitade, M., Yoshiji, H., Noguchi, R., Ikenaka, Y., Kaji, K., Shirai, Y., Yamazaki, M., Uemura, M., Yamao, J., Fujimoto, M., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5193 · Cited by 43
Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Zhao, J., Hu, J., Cai, J., Yang, X., & Yang, Z. (2003) · PubMed · Cited by 43
Detection of Hypoxia Inducible Factors and Angiogenic Growth Factors during Foetal Endochondral and Intramembranous Ossification
Spiegelaere, W. D., Cornillie, P., Casteleyn, C. R., Burvenich, C., & Broeck, W. V. D. (2010) · Anatomia Histologia Embryologia · doi:10.1111/j.1439-0264.2010.01005.x · Cited by 41
Antiangiogenic therapy: Not just for cancer anymore? # †
Shah, V. H., & Bruix, J. (2009) · Hepatology · doi:10.1002/hep.22872 · Cited by 38
Hepatic Artery Flow and Propranolol Metabolism in Perfused Cirrhotic Rat Liver
Couteur, D. G. L., Hickey, H. M., Harvey, P. J., Gready, J. E., & McLean, A. J. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38305-3 · Cited by 36
Regulation der Endothelfunktion und der Angiogenese durch den Vaskulären Endothelialen Wachstumsfaktor-A (VEGF-A)
Krøll, J., & Waltenberger, J. L. (2000) · Zeitschrift für Kardiologie · doi:10.1007/s003920050472 · Cited by 34
Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon Progression
Schwartz, J. D., Sung, M. W., Schwartz, M., Lehrer, D., Mandeli, J., Liebes, L., Goldenberg, A. S., & Volm, M. D. (2005) · The Oncologist · doi:10.1634/theoncologist.10-9-718 · Cited by 34
Review article: angiogenesis soluble factors as liver disease markers
Salcedo-Mora, X., Medina, J., Sanz-Cameno, P., Garcı́a-Buey, L., Martín‐Vílchez, S., & Moreno‐Otero, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02532.x · Cited by 33
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells
Giannelli, G., Azzariti, A., Sgarra, C., Porcelli, L., Antonaci, S., & Paradiso, A. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.11.005 · Cited by 31
Expresión génica en pacientes obesos con enfermedad hepática por depósito de grasa
Cayon, A., Crespo, J., Guerra, A. R., & Pons‐Romero, F. (2008) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082008000400004 · Cited by 29
Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Yanase, K., Namisaki, T., Kitade, M., Yamazaki, M., Tsujinoue, H., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.03.001 · Cited by 28
Sinusoidal Capillarization and Arterial Blood Supply Continuously Proceed with the Advance of the Stages of Hepatocarcinogenesis in the Rat
Yamamoto, T., Kaneda, K., Hirohashi, K., Kinoshita, H., & Sakurai, M. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb00244.x · Cited by 26
Relationship of the Microvascular Type to the Tumor Size, Arterialization and Dedifferentiation of Human Hepatocellular Carcinoma
Yamamoto, T., Hirohashi, K., Kaneda, K., Ikebe, T., Mikami, S., Uenishi, T., Kanazawa, A., Takemura, S., Shuto, T., Tanaka, H., et al. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02141.x · Cited by 25
Inhibition of mTOR suppresses experimental liver tumours.
Rizell, M., & Lindnér, P. (2005) · PubMed · Cited by 25
Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors
Hsu, C., Chen, C., Chen, L., Wu, C.-Y., Hsieh, F., & Cheng, A. (2005) · Radiology · doi:10.1148/radiol.2352040271 · Cited by 25
Induction of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 via CD47 Signaling in Neurovascular Cells
Xing, C., Arai, K., Park, K., & Lo, E. H. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0159-6 · Cited by 22
Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial
Pinter, M., Wichlas, M., Schmid, K., Plank, C. M., Müller, C., Wrba, F., & Peck‐Radosavljevic, M. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283036740 · Cited by 21
Tyrosine kinase inhibitors to treat liver cancer
Huynh, H. T. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903571659 · Cited by 20
HEPATOCELLULAR CARCINOMA
Gonzalez, K. B., & Woodall, M. L. (2001) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02581-6 · Cited by 19
Rapamycin prevents mesenteric neo‐angiogenesis and reduces splanchnic blood flow in portal hypertensive mice
Geerts, A. M., Vanheule, E., Vlierberghe, H. V., Leybaert, L., Steenkiste, C. V., Vos, M. D., & Colle, I. O. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00369.x · Cited by 16
Self-citation
Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression
Xiong, Y., Sun, H., Zhu, X., Zhang, W., Zhuang, P., Zhang, J., Xu, H., Kong, L., Wu, W., Qin, L., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0914-8 · Cited by 15
Cell density regulates prolyl 4-hydroxylase activity independent of mRNA levels
Lee, E. H., Kao, W. W. ‐., & Schwarz, R. I. (2001) · Matrix Biology · doi:10.1016/s0945-053x(00)00123-2 · Cited by 14
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib
Yau, T. C. C., Pang, R. W. C., Chan, P., & Poon, R. T. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003724705 · Cited by 14
Splenic infarction and bevacizumab
Malka, D., den Eynde, M. V., Boige, V., Dromain, C., & Ducreux, M. P. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70980-9 · Cited by 12
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
Shiah, H.-S., Chao, Y., Chen, L., Yao, T., Huang, J.-D., Chang, J., Chen, P., Chuang, T.-R., Chin, Y.-H., Whang‐Peng, J., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0203-z · Cited by 12
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
Wich, C. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i28.3592 · Cited by 9
Letter to the Editor
Ferrero, S., & Ragni, N. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.08.924 · Cited by 8
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
CHRISTINA, C., Wich, Abbas, Agaimy, Deike, Strobel, Thaddaus, WissniowskiArndt, Hartmann, C., Matthias, G., et al. (2010) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 5
Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma
Jung, H. S., Byun, G.-W., Lee, K.-E., Mun, Y., Nam, S. H., Kwon, J. M., Lee, S. N., Im, S., Seong, C., & Lee, S. N. (2005) · Cancer Research and Treatment · doi:10.4143/crt.2005.37.6.370 · Cited by 5
Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study
Han, S. H., Park, S. H., Kim, J. H., Lee, J. J., Kwon, S. Y., Kwon, O. S., Kim, S. S., Kim, J. H., Kim, K. K., Park, Y. H., et al. (2006) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2006.21.4.225 · Cited by 5
[Innovative use of the vascular endothelial growth factor in an experimental model of acute liver failure].
Marino, G., Piazzese, E., Gruttadauria, S., Nicotra, G. C., Guarnaccia, M., Emmanuele, G., Francesco, E. D., Travali, S., Bartoloni, G., Messina, A. A., et al. (2004) · PubMed · Cited by 5
Pyruvate-induced Long-term Maintenance of Glutathione S-Transferase in Rat Hepatocyte Cultures
Vanhaecke, T., Foriers, A., Geerts, A. E., Shephard, E. A., Vercruysse, A., & Rogiers, V. (2001) · Alternatives to Laboratory Animals · doi:10.1177/026119290102900324 · Cited by 4
Self-citation
Low dose of thalidomide can be effective in advanced hepatocellular carcinoma
Chen, S., Tsai, H., Jan, C., Wang, Y., & Chen, L. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04303.x · Cited by 3
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Chen, W.-C., Chen, W., Tseng, G.-C., Lai, H.-C., Shih, C., & Hsia, T. C. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02239.x · Cited by 2
Antiangiogenic therapy
Avitabile, T. (2010) · BMC Geriatrics · doi:10.1186/1471-2318-10-s1-l4 · Cited by 1

Research works printed but not linked: 2

Ko, 2002, Nuclear factor kappaB dependency of platelet-activating factor-induced angiogenesis, Cancer Res, 62, 1809
Cayon, 2008, Gene expression in obese patients with non-alcoholic steatohepatitis, Rev Esp Enferm Dig, 100, 212

Sorted by citations

Hypoalbuminemia: Pathogenesis and Clinical Significance
Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1451 · Cited by 1,448
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernández–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 726
Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease
Hammoutene, A., & Rautou, P.-E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.012 · Cited by 364
Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions
Iwakiri, Y., Shah, V. H., & Rockey, D. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.05.047 · Cited by 323
Hepatic microcirculation and mechanisms of portal hypertension
Gracia‐Sancho, J., Marrone, G., & Fernández‐Iglesias, A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 295

See all 277

Authors: Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H.
Affiliations: Ghent University (BE)
ORCID: Heindryckx, Femke
Geerts, Anja
Colle, Isabelle
Venue: Liver International
Publisher: Wiley
Published: 2010-11-15
Volume: 31
Issue: 2
Pages: 146-162
ISSN: 0106-9543 (ISSN-L)
1478-3223
DOI: 10.1111/j.1478-3231.2010.02369.x
OpenAlex: W1484083850
Cited by: 276
References: 194
Citations by year: 2026: 13 · 2025: 11 · 2024: 17 · 2023: 19 · 2022: 15 · 2021: 24 · 2020: 14 · 2019: 13 · 2018: 20 · 2017: 25 · 2016: 22 · 2015: 26 · 2014: 25 · 2013: 12 · 2012: 14
FWCI: 1.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1751 d)
Locations: Liver International (publishedVersion)
PubMed (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords: angiogenesis, chronic liver disease, portal hypertension, liver fibrosis, liver cirrhosis, nonalcoholic steatohepatitis, hepatocellular carcinoma, hypoxia, oxidative stress, inflammation, shear stress, hepatic microvasculature, anti-angiogenic therapy, disease progression
MeSH terms: Chronic Disease, Fatty Liver, Fibroblast Growth Factors, Carcinoma, Hepatocellular, Humans, Hypertension, Portal, Liver Cirrhosis, Liver Neoplasms, Models, Biological, Neovascularization, Pathologic, Platelet-Derived Growth Factor, Signal Transduction, Cadherins, Integrins, Disease Progression, Thrombospondins, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Angiopoietins, Angiostatins, Endostatins, Hypoxia-Inducible Factor 1, Microvessels, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiogenesis in chronic liver disease and its complications: Angiogenesis in CLD

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks